AF
VTGN icon

Amalgamated Financial’s VistaGen Therapeutics VTGN Stock Holding History

Amalgamated Financial’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$38K Buy
+1,012
New +$44.1K ﹤0.01% 2542

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

Amalgamated Financial's VTGN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in VistaGen Therapeutics (VTGN) in Q1 2022: 1,012 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #2542 among its holdings.

116 funds tracked by Wall St. Rank hold VTGN as of Q1 2022.

  • Amalgamated Financial held 1,012 shares of VistaGen Therapeutics worth $38K as of Q1 2022.
  • VistaGen Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • VistaGen Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2542 holding.
  • 116 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.